Hisun Pharm Hangzhou's Generic Daptomycin Receives Approval In US
SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. CHIPSCREEN BIOSCIENCES will exclusively grant HISUN PHARMACEUTICAL the right to promote Bilessglu® (Chiglitazar Sodium tablets), independently developed and manufactured by its wholly-owned subsidiary CHENGDU CHIPSCREEN PHARMACEUTICAL CO., LTD., in 19 provinces and regions in China. This cooperation intends to quickly provide to Chinese patients with this innovative diabetes treatment mechanism. CHIPCREEN BIOSCIENCES remains as the owner and manufacturer of the drug. Dr. Lu Xianping, Chairman of CHIPCREEN BIOSCIENCES, and Mr. Li Yan, President of HISUN PHARMACEUTICAL, signed a granting agreement, marking a milestone for the two parties to establish a long-term, stable and mutually beneficial strategic partnership.
SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. CHIPSCREEN BIOSCIENCES will exclusively grant HISUN PHARMACEUTICAL the right to promote Bilessglu® (Chiglitazar Sodium tablets), independently developed and manufactured by its wholly-owned subsidiary CHENGDU CHIPSCREEN PHARMACEUTICAL CO., LTD., in 19 provinces and regions in China. This cooperation intends to quickly provide to Chinese patients with this innovative diabetes treatment mechanism. CHIPCREEN BIOSCIENCES remains as the owner and manufacturer of the drug. Dr. Lu Xianping, Chairman of CHIPCREEN BIOSCIENCES, and Mr. Li Yan, President of HISUN PHARMACEUTICAL, signed a granting agreement, marking a milestone for the two parties to establish a long-term, stable and mutually beneficial strategic partnership.
TAIZHOU, China, Aug. 26, 2020 /PRNewswire/ -- Recently, Preprints with The Lancet has published a preliminary study report on Turkey's using Favipiravir produced by Hisun to treat COVID-19. The report says after Favipiravir was used in hospitals across Turkey for five days, the overall ICU patient admission rate in the country was reduced by half and that for patients under 60 years old dropped from nearly 20% to 6.6%, with a significant decline in the intubation rate (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3622357).
TAIZHOU, China, July 30, 2020 /PRNewswire/ -- According to news on June 29 from Middle East News Agency, Favipiravir, the popular drug used for treating COVID-19 has shown excellent results in clinical tests. AP, Fox and Deutsche Presse-Agentur have also reported the important role of Favipiravir in the successful fight against the virus in China.
TAIZHOU, China, June 23, 2020 /PRNewswire/ -- Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.
Hisun Pharm Hangzhou`s Generic Doxorubicin Hydrochloride Receives Approval in US
Hisun Pharm Hangzhou`s Generic Daunorubicin Hydrochloride Receives Approval in US
Hisun Pharm Hangzhou`s Generic Daunorubicin Hydrochloride Receives Approval in US
Hisun Pharm Hangzhou's Generic Ticagrelor Receives Approval in US